P13: Development of new pharmaceuticals with antiviraL and immunomodulatory activity for preventive maintenance and treatment of viral diseases, A.V.Sanin, A.N.Narovlyansky, A.V.Pronin
Deputy Director for Science
Name of organization:
Gamaleya Institute for Epidemiology and Microbiology of the Russian Academy of Medical Sciences
Development of new pharmaceuticals with antiviraL and immunomodulatory activity for preventive maintenance and treatment of viral diseases
Principal Investigators: - A.V.Sanin, Prof., Head Lab.of Cell-mediated immunity - A.N.Narovlyansky,Dr.Med.Sci Head, Lab of Cytokines - A.V.Pronin, Prof. Head Lab.Natural Immunity
Within the last two decades in the N.F.Gamaleya Research Institute of Epidemiology and Microbiology the directed search of pharmaceuticals with potent antiviral and immunomodulatory activity has been conducted. As a result, several drugs of such type were developed, tested, and even introduced into veterinary medicine practice. Besides, nowadays, a lot of new compounds are being developed and tested, including derivatives of plant origin polyprenols, and dolichols. In both experiments and primary field studies these compounds when screened for the antiviral activity were found to be superior to many well-known pharmaceuticals. They showed high performance for treatment of canine distemper, infections caused by enteroviruses, herpes, tick encephalitis, and other viral diseases, and were found to express a wide range of antiviral activity against HIV-infection, tick encephalitis, yellow fever, alpha-viral infection, hepatitis, etc. Preliminary data revealed ability of the compounds to infringe viral particles assembly, most effective with the enveloped viruses having a maturation stage of budding upon the plasmatic membrane of cells. Besides these compounds induce production of - and -interferons, and express different immunomodulatory activities (augment bactericidal activity of macrophages, reduce a permeability of lysosomal and cell membranes, stimulate natural killer cells activity, modulate interleukin 1 and 2 production). They are practically non-toxic, non-teratogenic, non-allergenic and non-mutagenic.
Objective of the work: On the basis of known and newly synthesized compounds earlier selected for their antiviral activity to develop new pharmaceuticals and their combinations effective for emergency preventive maintenance and treatment of viral diseases.
The project aims to develop novel and highly effective medicines for prevention and therapy of viral diseases. New potent antiviral drugs with immunomodulatory activity will be developed from the natural raw materials, preclinical and clinical testing of these drugs in animals will be performed parallel to development of the pilot production technology and methods of quality control.
Mechanisms of antiviral activity of the compounds will be further elucidated, and their molecular targets identified by use of subtractive hybridization and RT-PCR. Technology of the final form production will be developed, with parallel conducting of preclinical and, possibly, clinical tests. Preclinical proofs of safety and efficiency will be obtained. Besides, developed will be new technologies of antiviral and immunomodulatory drugs production that will help to protect wide groups of human beings and animals against common and emerging viral infections. Use of these drugs will also help to improve health of the patients with different immunodeficiencies, newborns, ailing people, patients receiving chemotherapy, etc.
Approximate cost of the Project realization is 850 000 US$.
Duration: 2-3 years.
A. Enterprises Corner
Enterprises looking for complementary partners in research arena and
Researchers offer their findings for technology transfer to enterprises
B. Research Corner
Research institutions looking for partners for joint research venture